Use of androgens at different stages of life: climacterium

Key points

• Female sexual dysfunction (FSD) includes hypoactive sexual desire disorders (HSDD) and sexual arousal, orgasm disorders and genito pelvic pain disorder, and vaginal penetration disorders.

• Female sexual dysfunction affects around 45% of women, most of them postmenopausal.

• The genitourinary menopause syndrome (GMS) includes signs and symptoms related to atrophy of the genital tract and predisposes to vaginal and/or urinary infections, in addition to interfering with the woman's sexual performance.

• There is a decline in cognitive function in postmenopausal women, and estrogens and androgens appear to independently influence cognitive activity.

• The characterization of postmenopausal androgen deficiency and the prescription of androgen therapy is still a controversial topic.

The National Specialty Commission on Gynecology Endocrinology of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO) endorses to this document. The content production is based on scientific studies on a thematic proposal and the findings presented contribute to clinical practice.

Publication History

Article published online:
29 January 2022

• References

• 1 Vegunta S, Kling JM, Kapoor E. Androgen therapy in women. J Womens Health (Larchmt) 2020; 29 (01) 57-64 DOI: 10.1089/jwh.2018.7494.
• 2 Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA. et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005; 165 (14) 1582-9 DOI: 10.1001/archinte.165.14.1582.
• 3 Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S. et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90 (09) 5226-33 DOI: 10.1210/jc.2004-1747.
• 4 Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I. et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study,”. Climacteric 2010; 13 (02) 121-31 DOI: 10.3109/13697131003675922.
• 5 Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L. et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the INTIMATE NM1 Study. Menopause 2006; 13 (05) 770-9 DOI: 10.1097/01.gme.0000243567.32828.99.
• 6 Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH. et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014; 99 (10) 3489-510 DOI: 10.1210/jc.2014-2260.
• 7 Clayton AH, Valladares Juarez EM. Female Sexual Dysfunction. Psychiatr Clin North Am 2017; 40 (02) 267-84 DOI: 10.1016/j.psc.2017.01.004.
• 8 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins – Gynecology. Female Sexual Dysfunction: ACOG Practice Bulletin Clinical Management Guidelines for Obstetrician-Gynecologists, Number 213. Obstet Gynecol 2019; 134 (01) e1-e18 DOI: 10.1097/AOG.0000000000003324.
• 9 Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M. et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008; 359 (19) 2005-17 DOI: 10.1056/NEJMoa0707302.
• 10 Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril 2017; 107 (02) 475-482.e15 DOI: 10.1016/j.fertnstert.2016.10.028.
• 11 Sood R, Shuster L, Smith R, Vincent A, Jatoi A. Counseling postmenopausal women about bioidentical hormones: ten discussion points for practicing physicians. J Am Board Fam Med 2011; 24 (02) 202-10 DOI: 10.3122/jabfm.2011.02.100194.
• 12 Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM. et al. Global Consensus Position Statement on the use of testosterone therapy for women. J Clin Endocrinol Metab 2019; 104 (10) 4660-6 DOI: 10.1210/jc.2019-01603.
• 13 Glaser R, Kalantaridou S, Dimitrakakis C. Testosterone implants in women: pharmacological dosing for a physiologic effect. Maturitas 2013; 74 (02) 179-84 DOI: 10.1016/j.maturitas.2012.11.004.
• 14 Manica D, Nucci M. Sob a pele: implantes subcutâneos, hormônios e gênero. Horiz Antropol 2017; 23 (47) 93-129 DOI: 10.1590/s0104-71832017000100004.
• 15 Bell RJ, Rizvi F, Islam RM, Davis SR. A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause 2018; 25 (06) 704-709 DOI: 10.1097/GME.0000000000001052.
• 16 Traish AM, Vignozzi L, Simon JA, Goldstein I, Kim NN. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev 2018; 6 (04) 558-71 DOI: 10.1016/j.sxmr.2018.03.005.
• 17 Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev 2015; 1: CD011066 DOI: 10.1002/14651858.CD011066.pub2.
• 18 Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol 2019; 7 (10) 754-66 DOI: 10.1016/S2213-8587(19)30189-5.
• 19 Kagan R, Kellogg-Spadt S, Parish SJ. Practical treatment considerations in the management of genitourinary syndrome of menopause. Drugs Aging 2019; 36 (10) 897-908 DOI: 10.1007/s40266-019-00700-w.
• 20 Simon JA, Goldstein I, Kim NN, Davis SR, Kellogg-Spadt S, Lowenstein L. et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause 2018; 25 (07) 837-47 DOI: 10.1097/GME.0000000000001138.
• 21 Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN. et al. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. J Steroid Biochem Mol Biol 2016; 159: 142-153 DOI: 10.1016/j.jsbmb.2016.03.016.
• 22 Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab 2018; 103 (11) 4146-54 DOI: 10.1210/jc.2018-01345.
• 23 Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G. et al. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause 2015; 22 (12) 1289-95 DOI: 10.1097/GME.0000000000000470.
• 24 Aziz A, Brännström M, Bergquist C, Silfverstolpe G. Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being. Fertil Steril 2005; 83 (04) 1021-1028 DOI: 10.1016/j.fertnstert.2004.12.008.
• 25 Pike CJ, Carroll JC, Rosario ER, Barron AM. Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol 2009; 30 (02) 239-58 DOI: 10.1016/j.yfrne.2009.04.015.
• 26 Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001; 86 (01) 158-61 DOI: 10.1210/jcem.86.1.7103.
• 27 Möller MC, Bartfai AB, Rädestad AF. Effects of testosterone and estrogen replacement on memory function. Menopause 2010; 17 (05) 983-989 DOI: 10.1097/gme.0b013e3181dc2e40.
• 28 Wisniewski AB, Nguyen TT, Dobs AS. Evaluation of high-dose estrogen and high-dose estrogen plus methyltestosterone treatment on cognitive task performance in postmenopausal women. Horm Res 2002; 58 (03) 150-155 DOI: 10.1159/000064491.
• 29 Davis SR, Shah SM, McKenzie DP, Kulkarni J, Davison SL, Bell RJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metab 2008; 93 (03) 801-808 DOI: 10.1210/jc.2007-2128.
• 30 Grimley Evans J, Malouf R, Huppert F, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev 2006; (04) CD006221 DOI: 10.1002/14651858.CD006221.
• 31 Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P. Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol (Oxf) 1998; 48 (02) 169-173 DOI: 10.1046/j.1365-2265.1998.3691182.x.
• 32 Khosla S, Riggs BL, Robb RA, Camp JJ, Achenbach SJ, Oberg AL. et al. Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. J Clin Endocrinol Metab 2005; 90 (09) 5096-5103 DOI: 10.1210/jc.2005-0396.
• 33 Popat VB, Calis KA, Kalantaridou SN, Vanderhoof VH, Koziol D, Troendle JF. et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 2014; 99 (09) 3418-26 DOI: 10.1210/jc.2013-4145.
• 34 Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995; 85 (04) 529-37 DOI: 10.1016/0029-7844(94)00448-M.